<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958500</url>
  </required_header>
  <id_info>
    <org_study_id>2019/3-1116-608</org_study_id>
    <nct_id>NCT03958500</nct_id>
  </id_info>
  <brief_title>The Problem of Colorectal Anastomosis Safety</brief_title>
  <acronym>ANSCRS</acronym>
  <official_title>Problem of Safety of Anastomosis in Colorectal Surgery and Search for the Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vilnius University hospital Santaros klinikos, Vilnius, Lithuania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, Lithuania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort pilot study. The investigators are planning to develop an
      original, standardized colorectal anastomosis inspection method, which will systemically
      inspect the anastomosis vascularity using the indocyanine green fluorescent angiography
      intraluminally and intraperitoneally, the air leak test, the methylene blue test, the tension
      in the anastomosis inspection, patients' risk factors scale sum. The summarized evaluation
      will determine the final anastomotic leak risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of anastomotic leakage</measure>
    <time_frame>0 to 60 days</time_frame>
    <description>The number of patients, who had clinical or radiological anastomotic leakage. Proctography will be performed 6-8 days and 4-6 weeks after the primary operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life before and after the operation</measure>
    <time_frame>0 to 60 days</time_frame>
    <description>Using low anterior resection syndrome score (the LARS score - simple 5 question questionnaire). LARS score is a tool consisting of five items, which are as follows: incontinence due to flatus (score range from 0 to 7), incontinence due to liquid stools (score range from 0 to 3), frequency of bowel movements (score range from 0 to 5), clustering (score range from 0 to 11) and urgency (score range from 0 to 16). The severity of each item is calculated on a scale ranging from 0 to 42, with a score of 0-20 (no LARS), 21-29 (minor LARS) and 30-42 (major LARS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before and after the operation</measure>
    <time_frame>0 to 60 days</time_frame>
    <description>Using QLQ-C30 questionnaire. To compare change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30 (Version 3)) before operation and 4-6 weeks after the operation.
The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.
The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 (&quot;very poor&quot;) to 7 (&quot;excellent&quot;). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>0 to 60 days</time_frame>
    <description>Patients, who needed re-interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative test leakage</measure>
    <time_frame>0 to 600 minutes</time_frame>
    <description>Leakage rate detected intraoperatively after anastomosis testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of anastomosis testing</measure>
    <time_frame>0 to 600 minutes</time_frame>
    <description>Time from the start of the anastomosis testing till the end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>0 to 600 minutes</time_frame>
    <description>Time from the start of the operation until the end of the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 days mortality</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>the mortality of the patients after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of anastomosis leakage</measure>
    <time_frame>0 to 60 days</time_frame>
    <description>In days after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Comprehensive anastomotic testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients undergo:
Indocyanine green fluorescent angiography intraluminally and intraperitoneally
Air leak test
Methylene blue test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Indocyanine green fluorescent angiography intraluminally and intraperitoneally</intervention_name>
    <description>The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis</description>
    <arm_group_label>Comprehensive anastomotic testing</arm_group_label>
    <other_name>Air leak test</other_name>
    <other_name>Methylene blue test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients over 18 year

          -  signed written consent

          -  a colorectal anastomosis lower 15 cm from anal verge

          -  elective surgery

        Exclusion Criteria:

          -  allergy to indocyanine green dye

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eligijus Poskus, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University, Vilnius, Lithuania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marius Kyzauskas</last_name>
    <phone>+37062214027</phone>
    <email>marius.kryzauskas@santa.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomas Poskus, prof.</last_name>
    <phone>+37068678893</phone>
    <email>tomas.poskus@santa.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute, Vilnius, Lithuania</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrius Dulskas, PhD.</last_name>
      <phone>+37067520094</phone>
      <email>audrius.dulskas@nvi.lt</email>
    </contact>
    <investigator>
      <last_name>Justas Kuliavas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rimantas Bausys</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenijus Stratilatovas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrius Dulskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Poskus</last_name>
      <phone>+37068678893</phone>
      <email>tomas.poskus@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Marius Kryzauskas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eligijus Poskus</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augustinas Bausys</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matas Jakubauskas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ugne Imbrasaite</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabija Makunaite</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kestutis Strupas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomas Poskus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Marius Kryzauskas</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

